All In Biotech

Drug Trial Radar · NCT04960579

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

275

Planned (sponsor's estimate)

Start

May 5, 2022

Primary completion

Mar 2029

Study completion Mar 2042

Sponsor

Lead sponsor
Poseida Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Roche-Genentech
First posted
Jul 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

Conditions

  • Multiple Myeloma

Interventions

  • P-BCMA-ALLO1 CAR-T cellsBiological

    Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy

  • RimiducidDrug

    Safety switch activator

  • MethotrexateDrug

    Anti-metabolite

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Part 1: Assess the safety and maximum tolerated dose (MTD) of P-BCMA-ALLO1 based on dose limiting toxicities (DLT)Time frame: Baseline through Day 28
  2. Phase 1 Part 2: Assess the safety and tolerability of P-BCMA-ALLO1 when administered as a fixed dose of cells.Time frame: Baseline through 36 months
  3. Phase 1b: The effect of cell dose and study armTime frame: Baseline through 36 months

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Goodyear, Arizona

  • University of California San Diego

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • Emory University

    Atlanta, Georgia

  • Blood Marrow and Transplant Group of Georgia

    Atlanta, Georgia

  • City of Hope

    Chicago, Illinois

  • Advocate Aurora Health

    Park Ridge, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Wayne State - Karmanos Cancer Institute

    Detroit, Michigan

  • Hackensack Meridian Health

    Hackensack, New Jersey

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Mount Sinai

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Oklahoma, Health Sciences Center

    Oklahoma City, Oklahoma

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Sarah Cannon Research Institute - St. David's South Austin Medical Center

    Austin, Texas

  • Houston Methodist Research Institute

    Houston, Texas

  • Sarah Cannon Research Institute - Methodist Healthcare

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.